Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab Biomarker Study in Advanced Melanoma
NCT00261365Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2005
- Primary completion
- Oct 2007
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of ipilimumab in Malignant Melanoma (MM) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Candidate markers predictive of response and/or serious toxicity. Started Nov 2005; status: completed.
02
Drugs
ipilimumab
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT00261365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00261365.